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Stage Ta/T1 urothelial carcinoma of the bladder (Ta/T1 BC) has a marked tendency to recur. Besides histopathology, markers such as
CK20 expression and proliferation index (Ki67) have been shown to predict its clinical course. The replication-licensing factor
minichromosome maintenance protein 2 (Mcm2) is a marker of proliferative potential shown to be a promising prognostic marker in
various malignancies. The aim of the present study was to evaluate the prognostic value of Mcm2 in comparison to stage, grade, CK20
and Ki67. Initial sporadic Ta/T1 BC (n¼71) were evaluated for their expression of CK20, Ki67 and Mcm2 by immunohistochemistry
and tissue microarray technology. Prognostic power was analysed by univariate and multivariate Cox regression model for tumour
recurrence rate. Median follow-up period was 39 months. A total of 35% patients experienced recurrence. While CK20 was not
predictive, grade, Ki67 and Mcm2 were significantly related to recurrence rate in univariate Cox regression model. Only grade (HR
2.37; 95% CI 1.24–4.51; P¼0.009) and Mcm2 expression with a cutoff X40% (HR 5.81; 95% CI 2.41–14.00; Po0.001) were
independent predictors of recurrence rate in multivariate Cox regression analysis. In addition to grade, expression of Mcm2 is an
independent predictor of recurrence in Ta/T1 BC.
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Urothelial carcinoma of the bladder is the fifth most common
cancer. While it is mostly non-muscle-invasive (i.e. pTa and pT1)
at initial presentation, up to 70% of patients experience recurrent
disease and up to 15% will progress to muscle-invasive BC (Millan-
Rodriguez et al, 2000). While cases with favourable biological
behaviour are subject to intense and frequent surveillance without
need, patients with high-risk tumours are depending on close
monitoring. Thus reliable prognostic parameters differentiating
high- and low-risk patients with stage Ta/T1 urothelial carcinoma
of the bladder (Ta/T1 BC) might enable individual risk adapted
follow-up regimes. Despite high interobserver variation, histo-
logical grading is the most commonly used predictor of prognosis
in Ta/T1 BC (Tosoni et al, 2000). Two well-established markers of
recurrence are MIB-1 and CK20. CK20 is normally expressed by
umbrella cells. CK20 dedifferentiation (e.g. expression in the entire
urothelium or complete expression loss) has been related to
disease recurrence in Ta/T1 BC (Harnden et al, 1999). The
proliferation index MIB-1, an antibody detecting the nuclear
antigen Ki67 expressed by dividing cells, has been linked to
progression (van Rhijn et al, 2003; Lopez-Beltran et al, 2004).
Recently, analysis of minichromosome maintenance protein
(Mcm) expression has been demonstrated to have prognostic
value in prostate and renal cell cancer and B-cell lymphoma
(Meng et al, 2001, Rodins et al, 2002, Obermann et al, 2005).
Minichromosome maintenance proteins are presumed to regulate
replication by cyclical DNA unwinding and to be highly specific for
proliferation (Obermann et al, 2005). Minichromosome main-
tenance protein 5 has been shown to detect bladder cancer reliably
in voided urine (Stoeber et al, 1999). To our knowledge there are
only two studies investigating the expression of Mcm2 in bladder
cancer. Kru ¨ger et al (2003) showed Mcm2 expression to be the
only parameter predicting progression in 52 pT1 tumours.
Korkolopoulou et al (2005) found Mcm2 and Mcm5 to indicate
adverse outcome in 65 muscle invasive bladder cancers. The aim of
this study was to evaluate the prognostic value of CK20 and Ki67
and to evaluate their relation to Mcm2 in Ta/T1 BC randomly
chosen from a consecutive and unselected series.
MATERIALS AND METHODS
Patients
The study was approved by Institutional Review Board of the
University of Regensburg and all patients gave informed consent.
From the databank of the Department of Urology of the University
of Regensburg containing 1200 initial Ta/T1 BC undergoing
transurethral resection of the bladder (TURB) from 1985 to 2005,
100 patients with initial Ta/T1 BC were chosen by random
generator and samples retrieved from the Department of
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paraffin. Clinical charts were reviewed and follow-up data were
collected. All slides were reviewed by one uropathologist (AH).
Tumour stage and grade were assigned according to the TNM
(UICC, 2002) and WHO classification of malignant tumours of the
urinary tract (Mostofi et al, 1973). All patients underwent control
TURB 4–6 weeks after the initial TURB. Adjuvant therapy and
follow-up procedure were initiated as reflected by appropriate
guidelines (Oosterlinck et al, 2002).
Tissue microarray and immunohistochemistry
Tissue microarrays (TMA) were constructed (Klopocki et al, 2004)
and expression of Mcm2, Ki67 and CK20 was evaluated by
immunohistochemistry (IHC) using standard staining procedures
as described previously (Harnden et al, 1999; Lopez-Beltran et al,
2004; Obermann et al, 2005). Antigen retrieval was carried out in
a microwave (250W for 30min, in a citrate solution; pH 6.0). The
sections were incubated with primary monoclonal antibodies for
Mcm2 (mouse monoclonal, clone 46, BD Biosciences, San Jose,
USA, dilution 1:3000), CK20 (clone IT-Ks 20.8; DAKO, Glostrup,
Denmark; dilution 1:100) and Ki67 (mouse monoclonal, clone
MIB-1, DAKO, Hamburg, Germany, dilution 1:50). Negative
controls were obtained by omitting the primary antibody.
Standard procedures were used for visualisation (ABC-Elite,
Vector-Laboratories, Burlingame, CA, USA). Diaminobenzidine
was used as chromogen. The slides were evaluated without
knowledge of clinical data. Immunoreactivity for CK20 and Ki67
was scored according to previously validated criteria (Harnden
et al, 1999; Lopez-Beltran et al, 2004). CK20 staining pattern was
scored normal in cases with expression in superficial umbrella
cells and absence in the intermediate or basal urothelial cell layers;
diffuse immunostaining (410%) or lack of CK20 expression was
scored abnormal as described previously (Harnden et al, 1999).
High Ki67 labeling index was defined if X15% of the tumour cells
were stained as described previously (Lopez-Beltran et al, 2004).
Immunoreactivity to Mcm2 was evaluated in 20% steps (Figure 1).
Statistical analysis
Statistical analyses were completed using SPSS version 12.0. (SPSS,
Chicago, IL, USA). P-values o0.05 were considered significant.
Contingency table analysis and two-sided Fisher’s exact tests
were used to study the statistical association between the groups.
Significant differences concerning tumour recurrence rate were
calculated using the Kaplan–Meier method and log-rank test. For
the evaluation of tumour recurrence rate, patients were surveyed at
the time of their last tumour-free clinical follow-up appointment.
Univariate and multivariate Cox regression models concerning
tumour recurrence rate were adjusted, testing the independent
prognostic relevance of the parameters analysed.
RESULTS
Clinical data and histopathology
Only cases with follow-up information were included in the
analysis. Follow-up data could be obtained from 71 out of 100
patients who were included in the analysis while 29 patients were
omitted. The 29 cases dropping out were distributed evenly across
pTa, pT1, all grades, CK20, Ki67 and Mcm2 expression. Median
age at the time of diagnosis was 71 years (range: 52–94 years). The
female proportion was 30% (n¼21). A total of 90% (n¼64) were
in stage pTa and 10% (n¼7) in pT1, respectively. Grade was
distributed as follows: G1 43% (n¼31), G2 46% (n¼33) and G3
10% (n¼7). Median follow-up was 39 months (range: 1–133
months). The median follow-up in cases with recurrence was 37
months (range: 4–97 months) and in cases without recurrence 40
months (range: 1–133 months). The use of adjuvant therapy with
mitomycin and BCG was distributed evenly between cases with and
without recurrence.
Recurring disease occurred in 35% (n¼25) of patients.
Progression to muscle invasive disease was noted in 6% (n¼4)
of cases. Thus progression risk was not statistically analysed due to
small numbers.
AB
C
Figure 1 (A–C) Minichromosome maintenance protein 2 expression in a non-invasive papillary bladder cancer (pTa, low grade) showing levels of
o20% (A  200) 60% (B  50 and C  200).
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Stage and grade: While stage (pTa vs pT1; P¼0.656) was not
related to disease recurrence, grade was significantly correlated to
tumour recurrence (Po0.002; Table 1).
Ki67: Immunohistochemistry for Ki67 revealed a high prolifera-
tion index (X15%) in 30% of cases. High proliferation index was
significantly related to tumour recurrence (Po0.001; Table 1).
CK20: CK20 was abnormal as defined above in 60% of cases.
There was no relation between the expression pattern of CK20 and
disease recurrence (Table 1).
Mcm2: Mcm2 expression level was X40% in 29% of cases. Using
a cutoff level of 40%, there was a strong relation with tumour
recurrence (Po0.001; Table 1).
Predictive factors for recurrence rate in univariate analysis
Relationship by parameters studied and recurrence-free survival was
evaluated by univariate Cox regression analysis. No significant
relation to recurrence rate was found for stage, sex, age and CK20. In
contrast, grade (Po0.001), Ki67 (P¼0.002) and Mcm2 (Po0.001)
were found to be prognostic of recurrence (Figure 2; Table 2).
Predictive factors for recurrence rate in multivariate
analysis
Multivariate Cox regression analysis was used to determine
independent association of grade, stage, CK20, Ki67 and Mcm2
with recurrence. While stage, CK20 and Ki67 failed to demonstrate
independence, grade (HR 2.37; 95% CI 1.24–4.51; P¼0.009) and
Mcm2 expression X40% (HR 5.81; 95% CI 2.41–14.00; Po0.001)
were independent predictors of recurrence (Table 2).
DISCUSSION
The management of Ta/T1 BC of the bladder challenges urologists,
as 70% of cases recur and 10–15% progress to invasive disease
(Millan-Rodriguez et al, 2000). Completeness of excision has been
recognised as a major factor for tumour recurrence (Brausi et al,
2002). Despite control TURB in all 71 Ta/T1 BC of the present
series to enhance completeness of resection 35% experienced
recurrences. Histopathological evaluation is the gold standard to
predict clinical behaviour of Ta/T1 BC, despite recognised
limitations such as high interobserver variability (Tosoni et al,
2000). Numerous markers have been evaluated to enhance the
prognostic power of histopathological evaluation.
Two well-established markers are CK20 (Harnden et al, 1999)
and Ki67 (van Rhijn et al, 2003; Lopez-Beltran et al, 2004). Ki67 is
a commonly applied prognostic and diagnostic tool (van Rhijn
et al, 2003; Lopez-Beltran et al, 2004), as the Ki67 protein is present
in the nuclei of cells in the G1, S, and G2 phases of the cell cycle in
dividing cells as well as in mitosis but not in the G0 phase of
quiescent cells. Nevertheless it is unlikely that Ki67 reliably labels
the entire proliferative cell fraction. Ki67 shows some variation in
its expression in the G1 phase and may not be expressed in cells
entering the G1 from G0. Its expression pattern also changes
through the cell cycle so that the probability of detection by
immunohistochemical staining may vary. In some tumours, Ki67
does not appear to label all proliferating cells (Verheijen et al,
1989; Hashimoto et al, 2004). Recently Mcm2 has been proposed as
a valuable marker for tumour evaluation (Tachibana et al, 2005).
In contrast to Ki67, Mcm2 is an essential factor for initiation of
DNA replication in eukaryotic cells. Mcm family members are
highly conserved replication initiation factors assembling with
Cdt1 and Cdc6 proteins into pre-replicative complexes at origin
recognition complexes during G1 phase (Maiorano et al, 2006),
thereby licensing chromatin for replication in the subsequent S
phase. Minichromosome maintenance proteins are present in all
phases of the proliferative cell cycle but absent in quiescent or
terminal differentiated cells and in cellular senescence. This
defines the Mcm family as a novel class of proliferation marker
(Maiorano et al, 2006). The detection of Mcm2–7 in tissues can be
used to locate cells that have regained unscheduled proliferation
Table 1 Distribution of tumour recurrence rate
Recurrence P-value
Mcm2 (n¼69) Po0.001*
o40% 10/49 (20.4%)
X40% 15/20 (75.0%)
CK20 (n¼68) P¼0.791 (NS)
Normal 10/27 (37.0%)
Abnormal 15/41 (36.6%)
Ki67 (n¼66) P¼0.001*
o15% 11/46 (23.9%)
X15% 13/20 (65.0%)
Grade (n¼71) Po0.002*
G1 4/31 (12.9%)
G2+G3 21/40 (56.3%)
Stage (n¼71) P¼0.656 (NS)
Ta 22/64 (34.4%)
T1 3/7 (9.9%)
Tumour size (n¼71) P¼0.450 (NS)
o3cm 63/71 (89%)
X3cm 8/71 (11%)
Multifocality (n¼71) P¼0.149 (NS)
Unifocal 51/71 (72%)
Multifocal 20/71 (28%)
NS¼not significant; *Significance at Po0.05.
Table 2 (a) Univariate and Cox regression analysis of Mcm2, Ki67, CK20,
sex, age, grade, stage, tumour size and multifocality influencing tumour
recurrence in patients with UCB and (b) Multivariate Cox regression
analysis of Mcm2, Ki67, CK20, grade, stage, tumour size and multifocality
influencing tumour recurrence in patients with UCB
(a) HR 95% CI P-value
Ki67 3.39 1.50–7.68 0.002
CK20 1.37 0.58–3.24 0.481
Mcm2 4.75 2.12–10.65 o0.001
Stage 1.40 0.42–4.70 0.585
Grade 2.66 1.44–4.89 o0.001
Tumour size 6.87 3.13–10.89 o0.001
Multifocality 2.10 0.77–5.05 0.005
Sex 0.74 0.30–1.86 0.525
Age 1.01 0.98–1.04 0.814
(b) Stepwise reverse
selection
Adjusted HR 95% CI P-value
Ki67 1.20 0.37–3.93 0.761
CK20 1.79 0.71–4.50 0.216
Mcm2 5.81 2.41–14.00 o0.001
Stage 1.64 0.36–7.42 0.521
Grade 2.37 1.24–4.51 0.009
Tumour size 6.87 3.05–11.72 o0.001
Multifocality 2.10 0.70–4.45 0.003
Abbreviations: CI¼confidence interval, HR¼Hazard ratio, UCB¼urothelial carci-
noma of the bladder. Bold values represent P-values o0.05.
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showed that Mcms could act as excellent markers for tumour
evaluation (Tachibana et al, 2005).
We have evaluated CK20, Ki67 and Mcm2 in a consecutive and
unselected series of Ta/T1 BC. While previously studied in pT1
bladder cancer by Kru ¨ger et al (2003) and muscle-invasive bladder
disease by Korkolopoulou et al (2005), no data on Mcm2
expression in Ta/T1 BC have been published to date. Various cutoff
levels have been reported for the evaluation of Mcm2 expression
(Kru ¨ger et al, 2003; Korkolopoulou et al, 2005). A grouping using
20% steps proved to be most effective in our set; however, the exact
classification in 20% steps is not easily reproducible between
observers and discriminatory power was strongest between 0–20
and 81–100%. Since this grouping excludes many intermediate cases,
we have chosen a cutoff level of 40%.
In our set of data a pathological expression of CK20 was not
related to adverse clinical outcome. However, this finding has to be
put into a careful perspective, as there are no data yet on a possible
usefulness of CK20 in large sets of pT1 tumours. Furthermore,
using tissue microarray (TMA) instead of large sections of whole
tumour could lead to misjudgement of CK20 staining. In the
present study, TMA cores with the relatively large diameter of
1.5cm were constructed of most representative areas marked by
one uropathologist (AH). This approach has been reported to be
valid for the analysis of CK20 in Ta/T1 BC (van Oers et al, 2007).
Univariate Cox regression analysis showed grade, Ki67 and
Mcm2 to be significantly related to recurrence rate. In a
multivariate Cox regression model, Ki67 was no independent
predictor of recurrence rate in contrast to grade and Mcm2.
Thus Mcm2 was a prognostic factor superior to Ki67, as it was
independent and Mcm2 expression X40% indicated a 5.81-fold
increased hazard ratio.
Even taking confounding factors related to the limited size of the
present series, the lack of follow-up information in roughly one-
third of cases and the low number of pT1 cases into account and
putting the findings into a very careful perspective, our data
suggest Mcm2 expression to be superior to Ki67 in predicting the
clinical course of Ta/T1 BC. We were able to define a valid
threshold for the immunohistochemical evaluation of Mcm2, as
40% had a good discriminatory power for recurrence rate
(Po0.001). In conclusion, our data warrant further evaluation of
Mcm2 expression as a novel prognostic parameter for Ta/T1 BC.
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